Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome
, , , , y
17 mar 2022
Acerca de este artículo
Publicado en línea: 17 mar 2022
Páginas: 56 - 65
Recibido: 22 jun 2021
DOI: https://doi.org/10.2478/rjim-2021-0034
Palabras clave
© 2022 Hasan H. Yeter et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Yeter, Hasan H.
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Derici, Ulver
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Arinsoy, Turgay
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Altok, Kadriye
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Erten, Yasemin
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey
Guz, Galip
Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of MedicineAnkara, Turkey